β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer - PubMed (original) (raw)

. 2012 Jun;18(6):892-901.

doi: 10.1038/nm.2772.

Paloma Ordóñez-Morán, Isabel Puig, Irene Chicote, Oriol Arqués, Stefania Landolfi, Yolanda Fernández, José Raúl Herance, Juan D Gispert, Leire Mendizabal, Susana Aguilar, Santiago Ramón y Cajal, Simó Schwartz Jr, Ana Vivancos, Eloy Espín, Santiago Rojas, José Baselga, Josep Tabernero, Alberto Muñoz, Héctor G Palmer

Affiliations

Free article

β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer

Stephan P Tenbaum et al. Nat Med. 2012 Jun.

Free article

Abstract

The Wnt–β-catenin and PI3K-AKT-FOXO3a pathways have a central role in cancer. AKT phosporylates FOXO3a, relocating it from the cell nucleus to the cytoplasm, an effect that is reversed by PI3K and AKT inhibitors. Simultaneous hyperactivation of the Wnt–β-catenin pathway and inhibition of PI3K-AKT signaling promote nuclear accumulation of β-catenin and FOXO3a, respectively, promoting cell scattering and metastasis by regulating a defined set of target genes. Indeed, the anti-tumoral AKT inhibitor API-2 promotes nuclear FOXO3a accumulation and metastasis of cells with high nuclear β-catenin content. Nuclear β-catenin confers resistance to the FOXO3a-mediated apoptosis induced by PI3K and AKT inhibitors in patient-derived primary cultures and in corresponding xenograft tumors in mice. This resistance is reversed by XAV-939, an inhibitor of Wnt–β-catenin signaling. In the presence of high nuclear β-catenin content, activation of FOXO3a by PI3K or AKT inhibitors makes it behave as a metastasis inductor rather than a proapoptotic tumor suppressor. We show that it is possible to evaluate the β-catenin status of patients' carcinomas and the response of patient-derived cells to target-directed drugs that accumulate FOXO3a in the nucleus before deciding on a course of treatment. We propose that this evaluation could be essential to the provision of a safer and more effective personalized treatment.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Nat Rev Drug Discov. 2009 Aug;8(8):627-44 - PubMed
    1. PLoS One. 2009 Nov 24;4(11):e8013 - PubMed
    1. Cell. 2006 May 5;125(3):535-48 - PubMed
    1. Oncogene. 2008 Apr 7;27(16):2276-88 - PubMed
    1. Mol Cell Biol. 2009 Sep;29(18):4906-17 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources